CML-Patients in chronic phase having failed a prior attempt to stop imatinib or other TKIs therapy either within EURO-SKI or not and are pretreated at least one year with any TKI after 1st stop
Conditions
Brief summary
The primary endpoint is molecular relapse-free survival, measured at 12 months and 36 months after 2nd or 3rd stop.
Detailed description
overall survival and progression-free survival probabilities, Estimation of the number of patients in MR4.5 who would be eligible for stopping TKI therapy, The number of patients who regain MR4 and MR4.5 and the time to MR4 recovery, Outcome of molecular relapse-free survival at 12, 18, 24 and 36 months after TKI discontinuation
Interventions
Sponsors
Heidelberg University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is molecular relapse-free survival, measured at 12 months and 36 months after 2nd or 3rd stop. | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival and progression-free survival probabilities, Estimation of the number of patients in MR4.5 who would be eligible for stopping TKI therapy, The number of patients who regain MR4 and MR4.5 and the time to MR4 recovery, Outcome of molecular relapse-free survival at 12, 18, 24 and 36 months after TKI discontinuation | — |
Countries
Germany
Outcome results
None listed